Sinusitis Trials Should Use Superiority Instead Of Non-Inferiority Design – Cmte.
Executive Summary
Clinical trials for acute bacterial sinusitis therapies should be designed to show superiority of the investigative antimicrobial to placebo, members of FDA's Anti-Infective Drugs Advisory Committee said Oct. 29
You may also be interested in...
Antibiotic Trial Standards To Be Revised By FDA Under Congressional Mandate
Manufacturers of antibiotics need to get involved as FDA writes clinical trial guidance for antibiotic drugs, according to Bruce Burlington, an independent consultant and former Wyeth VP
Antibiotic Trial Standards To Be Revised By FDA Under Congressional Mandate
Manufacturers of antibiotics need to get involved as FDA writes clinical trial guidance for antibiotic drugs, according to Bruce Burlington, an independent consultant and former Wyeth VP
Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA
Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)